Skip to main content

Recombinant Human Serpin E1/PAI-1 Protein, CF Best Seller

R&D Systems, part of Bio-Techne | Catalog # 1786-PI

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
1786-PI-010

Key Product Details

Source

Sf 21 (stably transfected)

Accession #

Conjugate

Unconjugated

Applications

Inhibition Activity

Product Specifications

Source

Spodoptera frugiperda, Sf 21 (stably transfected)-derived human Serpin E1/PAI-1 protein
Met1-Pro402, with a C-terminal 10-His tag

Purity

>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Endotoxin Level

<1.0 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Ser22 & Val24

Predicted Molecular Mass

44 kDa

SDS-PAGE

43 kDa, reducing conditions

Activity

Measured by its ability to inhibit uPA cleavage of a peptide substrate, N-carbobenzyloxy-Gly-Gly-Arg-7-amido-4-methylcoumarin (Z-GGR-AMC).
The IC50 value is <13 nM, as measured under the described conditions.

Reviewed Applications

Read 1 review rated 5 using 1786-PI in the following applications:

Scientific Data Images for Recombinant Human Serpin E1/PAI-1 Protein, CF

Recombinant Human Serpin E1/PAI-1 Protein Enzyme Activity

Recombinant Human Serpin E1/PAI-1 Protein Enzyme Activity

Recombinant Human Serpin E1/PAI-1 (Catalog # 1786-PI) is measured by its ability to inhibit uPA cleavage of a peptide substrate, N-carbobenzyloxy-Gly-Gly-Arg-7-amido-4-methylcoumarin (Z-GGR-AMC).

Formulation, Preparation and Storage

1786-PI
Formulation Lyophilized from a 0.2 μm filtered solution in Sodium Acetate, NaCl and CHAPS.
Reconstitution Reconstitute at 500 μg/mL in sterile 50 mM Sodium Acetate and 100 mM NaCl, pH 5.5.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -20 to -70 °C as supplied.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Serpin E1/PAI-1

As a member of the Serpin superfamily of serine protease inhibitors, Serpin E1/PAI‑1 is the principal inhibitor of urokinase‑type plasminogen activator (uPA) and tissue‑type PA (1, 2). As important regulators of extracellular matrix remodeling, uPA and PAI‑1 play a major role in many processes such as angiogenesis, tumor invasion and obesity (2‑4). For example, uPA and PAI-1 are the only tumor prognostic factors validated at the highest level of evidence with regard to their clinical utility in breast cancer (5). The human PAI-1 is initially synthesized as 402 amino acid precursor with a N‑terminal signal peptide (6, 7). PAI‑1 may exist in one of two possible conformations, designated as active or latent (8). The purified rhPAI‑1 is active against rhuPA. The heterogeneity at the N‑terminus of the purified
rhPAI‑1 has been observed before for both the recombinant and native proteins (9).

References

  1. Silverman, G.A. et al. (2001) J. Biol. Chem. 276:33293.
  2. Stefansson, S. et al. (2003) Curr. Pharm. Des. 9:1545.
  3. Duffy, M.J. (2002) Clin. Chem. 48:1194.
  4. Juhan-Vague, I. et al. (2003) J. Thromb. Haemost. 1:1575.
  5. Harbeck, N. et al. (2002) Clin. Breast Cancer 3:196.
  6. Pannekoek, H. et al. (1986) EMBO J. 5:2539.
  7. Ginsburg, D. et al. (1986) J. Clin. Invest. 78:1673.
  8. Wang, Z. et al. (1996) Biochemistry 35:16443.
  9. Stromqvist, M. et al. (1994) Protein Expr. Purif. 5:309.

Long Name

Plasminogen Activator Inhibitor

Alternate Names

Nexin, PAI-1, PAI1, PLANH1

Entrez Gene IDs

5054 (Human); 18787 (Mouse)

Gene Symbol

SERPINE1

UniProt

Additional Serpin E1/PAI-1 Products

Product Documents for Recombinant Human Serpin E1/PAI-1 Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human Serpin E1/PAI-1 Protein, CF

For research use only

Loading...
Loading...
Loading...
Loading...